CHRS
Coherus Oncology·NASDAQ
--
--(--)
--
--(--)
6.86 / 10
Outperform
Financial analysis rates CHRS at 6.9/10, highlighting a solid interest-coverage ratio of 15.48% and positive Revenue-MV, yet asset valuation and revenue growth year-over-year raise concerns. Overall, the balance of factors leads to an optimistic fundamental outlook but with caveats.
Analysis Checks(6/10)
Revenue-MV
Value-1.08
Score3/3
Weight25.58%
1M Return10.54%
Value-1.08
Score3/3
Weight25.58%
1M Return10.54%
Days sales outstanding
Value553.18
Score0/3
Weight-9.04%
1M Return-5.18%
Value553.18
Score0/3
Weight-9.04%
1M Return-5.18%
Net income-Revenue
Value-0.17
Score2/3
Weight20.42%
1M Return8.45%
Value-0.17
Score2/3
Weight20.42%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.04%
1M Return-1.11%
Value15.48
Score2/3
Weight-2.04%
1M Return-1.11%
Asset-MV
Value-0.50
Score0/3
Weight14.57%
1M Return5.75%
Value-0.50
Score0/3
Weight14.57%
1M Return5.75%
Total operating revenue (YoY growth rate %)
Value57.72
Score0/3
Weight-9.46%
1M Return-6.11%
Value57.72
Score0/3
Weight-9.46%
1M Return-6.11%
Profit-MV
Value3.71
Score2/3
Weight20.40%
1M Return8.45%
Value3.71
Score2/3
Weight20.40%
1M Return8.45%
PB-ROE
Value-0.66
Score3/3
Weight27.66%
1M Return12.83%
Value-0.66
Score3/3
Weight27.66%
1M Return12.83%
Operating revenue (YoY growth rate %)
Value57.72
Score0/3
Weight-8.14%
1M Return-5.06%
Value57.72
Score0/3
Weight-8.14%
1M Return-5.06%
Cash-MV
Value-0.07
Score2/3
Weight20.05%
1M Return8.41%
Value-0.07
Score2/3
Weight20.05%
1M Return8.41%
Revenue-MV
Value-1.08
Score3/3
Weight25.58%
1M Return10.54%
Value-1.08
Score3/3
Weight25.58%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value57.72
Score0/3
Weight-9.46%
1M Return-6.11%
Value57.72
Score0/3
Weight-9.46%
1M Return-6.11%
Days sales outstanding
Value553.18
Score0/3
Weight-9.04%
1M Return-5.18%
Value553.18
Score0/3
Weight-9.04%
1M Return-5.18%
Profit-MV
Value3.71
Score2/3
Weight20.40%
1M Return8.45%
Value3.71
Score2/3
Weight20.40%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight20.42%
1M Return8.45%
Value-0.17
Score2/3
Weight20.42%
1M Return8.45%
PB-ROE
Value-0.66
Score3/3
Weight27.66%
1M Return12.83%
Value-0.66
Score3/3
Weight27.66%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.04%
1M Return-1.11%
Value15.48
Score2/3
Weight-2.04%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value57.72
Score0/3
Weight-8.14%
1M Return-5.06%
Value57.72
Score0/3
Weight-8.14%
1M Return-5.06%
Asset-MV
Value-0.50
Score0/3
Weight14.57%
1M Return5.75%
Value-0.50
Score0/3
Weight14.57%
1M Return5.75%
Cash-MV
Value-0.07
Score2/3
Weight20.05%
1M Return8.41%
Value-0.07
Score2/3
Weight20.05%
1M Return8.41%
Is CHRS fundamentally strong?
- CHRS scores 6.86/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 55.80% net margin, 1.44 P/E ratio, 2.95 P/B ratio, and 2760.00% earnings growth, these metrics solidify its Outperform investment rating.
